Furthermore, the nanoparticles effectively reduced immune cell infiltration and proinflammatory cytokine release, offering a novel therapeutic strategy for AKI.[89] Although this study used a model of IRI‐induced AKI rather than infection‐induced AKI, it converges on several key innate immune signaling pathways, including TLR9‐mediated responses, making it a promising candidate for septic‐AKI therapy. Here, TLR9 is linked to acute kidney injury.